CLINICAL TRIALS PROFILE FOR FILSPARI
✉ Email this page to a colleague
All Clinical Trials for FILSPARI
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05856760 ↗ | A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN | Not yet recruiting | Travere Therapeutics, Inc. | Phase 2 | 2023-05-01 | This is a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FILSPARI
Condition Name
Clinical Trial Locations for FILSPARI
Trials by Country
Clinical Trial Progress for FILSPARI
Clinical Trial Phase
Clinical Trial Sponsors for FILSPARI
Sponsor Name